DJ
Therapeutic Areas
Amphastar Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BAQSIMI (glucagon nasal powder) | Severe hypoglycemia | Commercial |
| Primatene Mist (epinephrine inhalation aerosol) | Mild asthma symptoms | Commercial |
| Ipratropium Bromide HFA Inhalation Aerosol | COPD / asthma | Commercial |
| Iron Sucrose Injection, USP | Iron deficiency anemia in chronic kidney disease | Commercial |
| Teriparatide Injection | Osteoporosis | Commercial |
| Enoxaparin Sodium Injection | Deep vein thrombosis prophylaxis | Commercial |
| Naloxone HCl Injection | Opioid overdose | Commercial |
| Amphadase (hyaluronidase injection) | Adjuvant to increase absorption/dispersion | Commercial |
Leadership Team at Amphastar Pharmaceuticals
DM
Dr. Mary Z. Luo
Chief Operating Officer & Director
MW
Mr. William J. Peters
Chief Financial Officer
MJ
Mr. Jason B. Shandell
Senior Vice President & General Counsel
MD
Mr. Dan Dischner
Senior Vice President, Human Resources
DM
Dr. Michael A. Zasloff
Independent Director
MR
Mr. Richard Prud'homme
Independent Director
MM
Ms. Maria Z. Li
Vice President, Corporate Controller